NCT06619210View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

May 29, 2023

Study Completion Date

May 29, 2023

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

HL231 Dose 1/2/3/4

HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer

Trial Locations (1)

610041

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY